AgingResearch.NewsJoin free

Vaxcyte

CompanyUnited StatesFounded 2013

Vaxcyte develops one asset, in phase 3 (VAX-31 in invasive pneumococcal disease). Mostly vaccine acting on inflammation; based in the United States, founded in 2013.

1
Asset
Furthest stage
Phase 3
0
Trials
0
Signals

Pipeline

1

  • VAX-31

    31-valent pneumococcal conjugate vaccine conferring protection against Streptococcus pneumoniae serotypes

    Phase 3, Vaccine, Inflammation, invasive pneumococcal disease, pneumococcal disease

Full company profiles: pipeline, trials, funding and people.

See Pro

In the full profile

  • Evidence behind the mechanisms1
  • Similar companies6

Intelligence